WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy
- PMID: 17636697
- DOI: 10.1002/14651858.CD002182
WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy
Abstract
Background: Diabetic peripheral neuropathy is a common complication of diabetes mellitus.
Objectives: To assess the efficacy of aldose reductase inhibitors in the prevention, reversal or delay in the progression of diabetic peripheral neuropathy.
Search strategy: The Cochrane Diabetes Group's database was searched and the citation lists of identified trials and previous reviews checked. Investigators identified as active in the field were approached for overlooked studies.
Selection criteria: Randomised controlled trials of aldose reductase inhibitors versus placebo, no treatment or other treatment in diabetic patients with or without clinical neuropathy.
Data collection and analysis: Nerve conduction velocity was the only end point measured in all trials. Treatment effect was evaluated in terms of nerve conduction velocity mean difference in median and peroneal motor and median and sural sensory nerves.
Main results: 19 trials, testing 4 different aldose reductase inhibitors for between 4 to 208 weeks duration (median 24 weeks), met the inclusion criteria for the meta-analysis. A small but statistically significant reduction in decline of median and peroneal motor nerve conduction velocities was present in the treated group when compared to the control group (weighted mean 0.66 m/s 95% CI 0.18-1.14 m/s and 0.53 m/s 95% CI 0.02-1.04m/s respectively). No clear benefit of aldose reductase inhibitor treatment was observed in either of the sensory nerves.
Authors' conclusions: Although aldose reductase inhibitor treatment has been demonstrated to diminish the reduction in motor nerve conduction velocity, the clinical relevance of such a change in this outcome measure is uncertain. There was no effect in terms of this outcome measure in the smaller sensory fibres, degeneration of which is primarily responsible for the most common neuropathic syndrome associated with diabetes, that of severe pain and loss of sensation in the extremity leading in some cases to ulceration and eventual amputation.
Update of
-
Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.Cochrane Database Syst Rev. 2000;1996(2):CD002182. doi: 10.1002/14651858.CD002182. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 1996 Apr 22;(1):CD002182. doi: 10.1002/14651858.CD002182. PMID: 10796870 Free PMC article. Updated.
Similar articles
-
Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.Cochrane Database Syst Rev. 2000;1996(2):CD002182. doi: 10.1002/14651858.CD002182. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 1996 Apr 22;(1):CD002182. doi: 10.1002/14651858.CD002182. PMID: 10796870 Free PMC article. Updated.
-
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.Diabet Med. 1996 Dec;13(12):1017-26. doi: 10.1002/(SICI)1096-9136(199612)13:12<1017::AID-DIA252>3.0.CO;2-Z. Diabet Med. 1996. PMID: 8973882
-
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.Diabetes Care. 2001 Oct;24(10):1776-82. doi: 10.2337/diacare.24.10.1776. Diabetes Care. 2001. PMID: 11574441 Clinical Trial.
-
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.Diabetes Care. 2006 Jul;29(7):1538-44. doi: 10.2337/dc05-2370. Diabetes Care. 2006. PMID: 16801576 Clinical Trial.
-
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?Curr Diab Rep. 2004 Dec;4(6):405-8. doi: 10.1007/s11892-004-0047-z. Curr Diab Rep. 2004. PMID: 15539002 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous